Viewing data from:

GADOTERATE MEGLUMINE

ANDA

GADOTERATE MEGLUMINE | A215304 | JIANGSU HENGRUI PHARMACEUTICALS CO LTD

5 strengths0 unique patents0 unique exclusivities

API Supply Chain7 active DMFs2 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

FORMOSA LABORATORIES INCGADOTERATE MEGLUMINE

DMF 341292019

INNOPHARMAX INCGADOTERATE MEGLUMINE

DMF 342912019

JIANGSU HENGRUI PHARMACEUTICALS CO LTDGADOTERATE MEGLUMINE

DMF 346732020

BIOPHORE INDIA PHARMACEUTICALS PVT LTDGADOTERATE MEGLUMINE

DMF 361482021

ANHUI POLY PHARM CO LTDGADOTERATE MEGLUMINE

DMF 370722022

VIWIT PHARMACEUTICAL CO LTDGADOTERATE MEGLUMINE

DMF 387392023

BEIJING BEILU PHARMACEUTICAL CO LTDGADOTERATE MEGLUMINE

DMF 409352024

VIWIT PHARMACEUTICAL CO LTDInactiveGADOTERATE MEGLUMINE (DRUG SUBSTANCE)

DMF 344212020

SICHUAN RENAN PHARMACEUTICAL CO LTDInactiveGADOTERATE MEGLUMINE

DMF 394892024

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (5)

Sort:

#001 — 1.8845GM/5ML (376.9MG/ML)

0 patents0 exclusivities▴

SOLUTION;INTRAVENOUS | Approved: Apr 11, 2022

No patent or exclusivity listings for this strength.

#002 — 3.769GM/10ML (376.9MG/ML)

0 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Apr 11, 2022

#003 — 5.6535GM/15ML (376.9MG/ML)

0 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Apr 11, 2022

#004 — 7.538GM/20ML (376.9MG/ML)

0 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Apr 11, 2022

#005 — 37.69GM/100ML (376.9MG/ML)

0 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Apr 15, 2022